نتایج جستجو برای: bromocriptine mesylate

تعداد نتایج: 4670  

2011

Desferal, deferoxamine mesylate USP, is an iron-chelating agent, available in vials for intramuscular, subcutaneous, and intravenous administration. Desferal is supplied as vials containing 500 mg and 2 g of deferoxamine mesylate USP in sterile, lyophilized form. Deferoxamine mesylate is N-[5-[3-[(5­ aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N­ hydroxyacetamido)pentyl]carbamoyl]p...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2006
Heather G Jørgensen Mhairi Copland Elaine K Allan Xiaoyan Jiang Allen Eaves Connie Eaves Tessa L Holyoake

PURPOSE Primitive quiescent chronic myeloid leukemia (CML) cells are biologically resistant to imatinib mesylate, an inhibitor of the p210(BCR-ABL) kinase. The present study was designed to investigate whether either continuous or intermittent exposure of these cells to granulocyte-colony stimulating factor (G-CSF) in vitro can overcome this limitation to the effectiveness of imatinib mesylate ...

Journal: :The Journal of clinical endocrinology and metabolism 1999
J Verhelst R Abs D Maiter A van den Bruel M Vandeweghe B Velkeniers J Mockel G Lamberigts P Petrossians P Coremans C Mahler A Stevenaert J Verlooy C Raftopoulos A Beckers

Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the effect on clinical symptoms, tumor shrinkag...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Roberta Vitali Camillo Mancini Vincenzo Cesi Barbara Tanno Mariateresa Mancuso Gianluca Bossi Ying Zhang Robert V Martinez Bruno Calabretta Carlo Dominici Giuseppe Raschellà

PURPOSE We assessed the relevance of Slug (SNAI2) for apoptosis resistance and invasion potential of neuroblastoma cells in vitro and in vivo. EXPERIMENTAL DESIGN We evaluated the effect of imatinib mesylate on invasion and analyzed the genes modulated by imatinib mesylate treatment in neuroblastoma cells. Slug expression, inhibited by imatinib mesylate treatment, was knocked down in neurobla...

On most adrenergic and cholinergic nerve terminals, prejunctional α-adrenoceptors belonging to the α2-subtype have been identified. Activation of these receptors will decrease the release of norepinephrine. It has been reported that several isolated tissue preparations contain prejunctional dopamine receptors, the stimulation of which inhibits neurotransmission. It has remained uncertain whethe...

B Habibi Asl K Hassanzadeh

The aim of this study was to investigate the effects of magnesium as a N-Methyl–D-Aspartate (NMDA) receptor Antagnist and bromocriptine as a dopamine receptor agonist on morphine dependence and withdrawal symptoms. In the present study different groups of mice were received morphine (50 mg/kg, i.p.) for four days and on fourth day 1.5 hour after the last morphine administration they received di...

ژورنال: ارمغان دانش 2020

Background: Effect of drugs on different receptors may cause effect and also unexpected side effects.  For example, using Dopamine as an anti-parkinson drug block the upper GnRH axis and thatchr('39')s why some sexual disorders happen. In this study, the effect of serotonin as Fluvoxamine injection on lower levels of GnRH by blocking the upper GnRH axis with injection of Bromocriptine was inves...

Aram Hamidi, Mehdi Nasr Esfahani,

Negative symptoms are still a major obstacle in the recovery of schizophrenic patients. Many attempts to develop novel drugs affecting negative symptoms of schizophrenia have yielded insignificant results. This study evaluates the effects of bromocriptine, a dopamine agonist, on negative symptoms of schizophrenia utilizing a placebo-controlled crossover double-blind clinical trial. Methodology:...

Journal: :Blood 2003
Junya Kuroda Shinya Kimura Hidekazu Segawa Yutaka Kobayashi Toshikazu Yoshikawa Yoshimasa Urasaki Takanori Ueda Fumio Enjo Harukuni Tokuda Oliver G Ottmann Taira Maekawa

Imatinib mesylate, a competitive inhibitor of Abl tyrosine kinase, is highly effective for the early stages of chronic myelogenous leukemia (CML), but remissions induced in advanced-phase CML and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia tend to be relatively short-lived. Therefore, the search for agents that enhance the anti-Ph+ effect of imatinib mesylate is warrante...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید